ACTRN12606000324516
Not yet recruiting
Phase 3
Randomised placebo-controlled double- blind study of unregistered drug MKTVIF75HV and unregistered drug ASFSADNS on cognition and disability in mild to moderate Alzheimer's disease
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Melbourne Health
- Enrollment
- 60
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Mild to moderate Alzheimer's disease (Mini mental state examination score of 12\-24\). The Alzheimer's disease was diagnosed by a specialist or specialist clinic. There may be co\-existing cerebrovascular disease or Parkinsonism subject to the exclusion criteria. On stable dose anticholinesterase therapy for at least 3 months or off such therapy (because failed it or could not tolerate it) for at least 3 months. Conversant in English. Consent obtained.
Exclusion Criteria
- •Prominent dysphasia.Defined abnormalities/levels on screening blood tests.History of renal calculi.History of GIT lesions which may affect absorption of MKTVIF75HV.Febrile illness greater than one day and/or IVI antibiotics and/or intravenous sedation or general anaesthesia within one month prior to first cognitive assessment.Past cranial neurosurgery, epilepsy or multiple sclerosis. Type one diabetes. Lesions which may affect compliance with study regimen.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
study to access the benefit of homoeopathic medicine Apis mellifica 6C in reducing cancer paiHealth Condition 1: G893- Neoplasm related pain (acute) (chronic)CTRI/2022/07/044248Sarada Krishna Homoeopathic Medical Collge Kulasekharam
Recruiting
Phase 3
Assessment of efficacy of lithium in prevention of peripheral neuropathyChemotherapy induce peripheral neuropathy.IRCT20160813029327N10Islamic Azad University44
Not yet recruiting
Phase 3
Comparing the use of oral misoprostol with vaginal misoprostol to facilitate spontaneous labourCTRI/2019/01/017318Fluid Research Grant
Completed
Not Applicable
Placebo-controlled, randomized double-blind study to evaluate the efficacy and tolerability of Rosaxan® in patients with GonarthrosisM17Gonarthrosis [arthrosis of knee]DRKS00009034medAgil Gesundheitsgesellschaft mbH92
Active, not recruiting
Phase 1
Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD – The ABACOPD StudyMedDRA version: 19.0 Level: LLT Classification code 10010953 Term: COPD exacerbation System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2012-003234-16-DEHannover Medical School represented by Hannover Clinical Trial Center GmbH980